NASDAQ:NAII

Natural Alternatives International Competitors

$18.20
+1.14 (+6.68 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.99
Now: $18.20
$18.27
50-Day Range
$14.36
MA: $16.05
$17.50
52-Week Range
$5.82
Now: $18.20
$18.50
Volume128,477 shs
Average Volume37,354 shs
Market Capitalization$115.72 million
P/E Ratio227.53
Dividend YieldN/A
Beta0.95

Competitors

Natural Alternatives International (NASDAQ:NAII) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying NAII stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Natural Alternatives International, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Canopy Growth (NASDAQ:CGC) and Natural Alternatives International (NASDAQ:NAII) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Canopy Growth has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and Natural Alternatives International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

Natural Alternatives International has lower revenue, but higher earnings than Canopy Growth.

Institutional & Insider Ownership

10.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by insiders. Comparatively, 26.4% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Canopy Growth and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Natural Alternatives International0.40%0.71%0.43%

Analyst Ratings

This is a summary of recent ratings and target prices for Canopy Growth and Natural Alternatives International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510211.94
Natural Alternatives International0000N/A

Canopy Growth currently has a consensus price target of $35.6778, suggesting a potential upside of 28.34%. Given Canopy Growth's higher possible upside, equities research analysts clearly believe Canopy Growth is more favorable than Natural Alternatives International.

Summary

Natural Alternatives International beats Canopy Growth on 7 of the 13 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and Natural Alternatives International (NASDAQ:NAII) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Aphria has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aphria and Natural Alternatives International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

Natural Alternatives International has lower revenue, but higher earnings than Aphria.

Institutional and Insider Ownership

10.3% of Aphria shares are held by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are held by institutional investors. 26.4% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Aphria and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
Natural Alternatives International0.40%0.71%0.43%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aphria and Natural Alternatives International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria05302.38
Natural Alternatives International0000N/A

Aphria currently has a consensus target price of $22.00, suggesting a potential upside of 55.59%. Given Aphria's higher possible upside, analysts plainly believe Aphria is more favorable than Natural Alternatives International.

Summary

Natural Alternatives International beats Aphria on 7 of the 12 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Natural Alternatives International (NASDAQ:NAII) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Cronos Group has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cronos Group and Natural Alternatives International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million117.46$1.17 billion$0.6712.48
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

Cronos Group has higher earnings, but lower revenue than Natural Alternatives International.

Institutional and Insider Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Comparatively, 26.4% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Cronos Group and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Natural Alternatives International0.40%0.71%0.43%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cronos Group and Natural Alternatives International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24101.86
Natural Alternatives International0000N/A

Cronos Group currently has a consensus target price of $8.75, suggesting a potential upside of 4.67%. Given Cronos Group's higher possible upside, analysts plainly believe Cronos Group is more favorable than Natural Alternatives International.

Tilray (NASDAQ:TLRY) and Natural Alternatives International (NASDAQ:NAII) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Tilray has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Valuation & Earnings

This table compares Tilray and Natural Alternatives International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million17.69$-321,170,000.00($1.69)-10.18
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

Natural Alternatives International has lower revenue, but higher earnings than Tilray.

Institutional and Insider Ownership

12.6% of Tilray shares are held by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are held by institutional investors. 16.8% of Tilray shares are held by insiders. Comparatively, 26.4% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Tilray and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
Natural Alternatives International0.40%0.71%0.43%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tilray and Natural Alternatives International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray19001.90
Natural Alternatives International0000N/A

Tilray currently has a consensus target price of $18.3078, suggesting a potential upside of 6.44%. Given Tilray's higher possible upside, analysts plainly believe Tilray is more favorable than Natural Alternatives International.

Summary

Natural Alternatives International beats Tilray on 7 of the 11 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Natural Alternatives International (NASDAQ:NAII) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Profitability

This table compares USANA Health Sciences and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Natural Alternatives International0.40%0.71%0.43%

Risk & Volatility

USANA Health Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Institutional and Insider Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Comparatively, 26.4% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for USANA Health Sciences and Natural Alternatives International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Natural Alternatives International0000N/A

USANA Health Sciences currently has a consensus target price of $126.00, suggesting a potential upside of 27.41%. Given USANA Health Sciences' higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than Natural Alternatives International.

Valuation & Earnings

This table compares USANA Health Sciences and Natural Alternatives International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

USANA Health Sciences has higher revenue and earnings than Natural Alternatives International.

Summary

USANA Health Sciences beats Natural Alternatives International on 11 of the 12 factors compared between the two stocks.

Natural Alternatives International (NASDAQ:NAII) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Natural Alternatives International and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natural Alternatives International0.40%0.71%0.43%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Volatility and Risk

Natural Alternatives International has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500.

Institutional and Insider Ownership

31.8% of Natural Alternatives International shares are held by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are held by institutional investors. 26.4% of Natural Alternatives International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Natural Alternatives International and Aurora Cannabis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natural Alternatives International0000N/A
Aurora Cannabis69001.60

Aurora Cannabis has a consensus target price of $10.9264, suggesting a potential upside of 38.66%. Given Aurora Cannabis' higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than Natural Alternatives International.

Valuation and Earnings

This table compares Natural Alternatives International and Aurora Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76

Natural Alternatives International has higher earnings, but lower revenue than Aurora Cannabis.

Summary

Natural Alternatives International beats Aurora Cannabis on 7 of the 11 factors compared between the two stocks.


Natural Alternatives International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80+1.4%$10.62 billion$297.34 million-8.32News Coverage
Aphria logo
APHA
Aphria
1.6$14.14+3.9%$4.48 billion$405.96 million-23.97Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
Cronos Group logo
CRON
Cronos Group
0.8$8.36+2.6%$3.01 billion$25.64 million34.83Analyst Downgrade
Tilray logo
TLRY
Tilray
1.0$17.20+1.5%$2.95 billion$166.98 million-3.79News Coverage
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89+2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88+1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85+1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52+3.3%$676.12 million$60.46 million-1.13Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20+4.0%$547.41 million$46.29 million-21.58
MediWound logo
MDWD
MediWound
1.4$5.04+2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
HAPP
Happiness Biotech Group
0.6$1.84+0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13+2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56+1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
CYAN
Cyanotech
0.6$3.14+1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.